Literature DB >> 34308902

How Well Does Subjective Cognitive Decline Correspond to Objectively Measured Cognitive Decline? Assessment of 10-12 Year Change.

Daniel E Gustavson1,2, Amy J Jak3,4, Jeremy A Elman3,5, Matthew S Panizzon3,5, Carol E Franz3,5, Katherine A Gifford2, Chandra A Reynolds6, Rosemary Toomey7, Michael J Lyons7, William S Kremen3,5,8.   

Abstract

BACKGROUND: Although not strongly correlated with current objective cognitive ability, subjective cognitive decline (SCD) is a risk factor for Alzheimer's disease. Most studies focus on SCD in relation to future decline rather than objective prior decline that it purportedly measures.
OBJECTIVE: We evaluated whether self-report of cognitive decline-as a continuous measure-corresponds to objectively-assessed episodic memory and executive function decline across the same period.
METHODS: 1,170 men completed the Everyday Cognition Questionnaire (ECog) at mean age 68 assessing subjective changes in cognitive ability relative to 10 years prior. A subset had mild cognitive impairment (MCI), but MCI was diagnosed without regard to subjective decline. Participants completed up to 3 objective assessments of memory and executive function (M = 56, 62, and 68 years). Informant-reported ECogs were completed for 1,045 individuals. Analyses controlled for depression and anxiety symptoms assessed at mean age 68.
RESULTS: Participant-reported ECog scores were modestly associated with objective decline for memory (β= -0.23, 95%CI [-0.37, -0.10]) and executive function (β= -0.19, 95%CI [-0.33, -0.05]) over the same time period. However, these associations were nonsignificant after excluding MCI cases. Results were similar for informant ratings. Participant-rated ECog scores were more strongly associated with concurrent depression and anxiety symptoms, (β= 0.44, 95%CI [0.36, 0.53]).
CONCLUSION: Continuous SCD scores are correlated with prior objective cognitive changes in non-demented individuals, though this association appears driven by individuals with current MCI. However, participants' current depression and anxiety ratings tend to be strongly associated with their SCD ratings. Thus, what primarily drives SCD ratings remains unclear.

Entities:  

Keywords:  Aging; cognitive decline; cognitive function; executive function; latent growth model; memory

Mesh:

Year:  2021        PMID: 34308902      PMCID: PMC8482061          DOI: 10.3233/JAD-210123

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  52 in total

1.  Genetic and environmental architecture of changes in episodic memory from middle to late middle age.

Authors:  Matthew S Panizzon; Michael C Neale; Anna R Docherty; Carol E Franz; Kristen C Jacobson; Rosemary Toomey; Hong Xian; Terrie Vasilopoulos; Brinda K Rana; Ruth McKenzie; Michael J Lyons; William S Kremen
Journal:  Psychol Aging       Date:  2015-05-04

2.  Stability of genetic and environmental influences on executive functions in midlife.

Authors:  Daniel E Gustavson; Matthew S Panizzon; Jeremy A Elman; Carol E Franz; Chandra A Reynolds; Kristen C Jacobson; Naomi P Friedman; Hong Xian; Rosemary Toomey; Michael J Lyons; William S Kremen
Journal:  Psychol Aging       Date:  2018-03

3.  Genetic complexity of episodic memory: a twin approach to studies of aging.

Authors:  William S Kremen; Matthew S Panizzon; Carol E Franz; Kelly M Spoon; Eero Vuoksimaa; Kristen C Jacobson; Terrie Vasilopoulos; Hong Xian; Jeanne M McCaffery; Brinda K Rana; Rosemary Toomey; Ruth McKenzie; Michael J Lyons
Journal:  Psychol Aging       Date:  2014-06

4.  Cognitive complaints correlate with depression rather than concurrent objective cognitive impairment in the successful aging evaluation baseline sample.

Authors:  Zvinka Z Zlatar; Raeanne C Moore; Barton W Palmer; Wesley K Thompson; Dilip V Jeste
Journal:  J Geriatr Psychiatry Neurol       Date:  2014-03-10       Impact factor: 2.680

5.  Genetic and environmental architecture of executive functions in midlife.

Authors:  Daniel E Gustavson; Matthew S Panizzon; Carol E Franz; Naomi P Friedman; Chandra A Reynolds; Kristen C Jacobson; Hong Xian; Michael J Lyons; William S Kremen
Journal:  Neuropsychology       Date:  2017-08-31       Impact factor: 3.295

6.  Implementation of subjective cognitive decline criteria in research studies.

Authors:  José L Molinuevo; Laura A Rabin; Rebecca Amariglio; Rachel Buckley; Bruno Dubois; Kathryn A Ellis; Michael Ewers; Harald Hampel; Stefan Klöppel; Lorena Rami; Barry Reisberg; Andrew J Saykin; Sietske Sikkes; Colette M Smart; Beth E Snitz; Reisa Sperling; Wiesje M van der Flier; Michael Wagner; Frank Jessen
Journal:  Alzheimers Dement       Date:  2016-11-05       Impact factor: 21.566

7.  Quantification of five neuropsychological approaches to defining mild cognitive impairment.

Authors:  Amy J Jak; Mark W Bondi; Lisa Delano-Wood; Christina Wierenga; Jody Corey-Bloom; David P Salmon; Dean C Delis
Journal:  Am J Geriatr Psychiatry       Date:  2009-05       Impact factor: 4.105

8.  Interaction between Alcohol Consumption and Apolipoprotein E (ApoE) Genotype with Cognition in Middle-Aged Men.

Authors:  Riki E Slayday; Daniel E Gustavson; Jeremy A Elman; Asad Beck; Linda K McEvoy; Xin M Tu; Bin Fang; Richard L Hauger; Michael J Lyons; Ruth E McKenzie; Mark E Sanderson-Cimino; Hong Xian; William S Kremen; Carol E Franz
Journal:  J Int Neuropsychol Soc       Date:  2020-07-14       Impact factor: 2.892

Review 9.  Memory loss in Alzheimer's disease.

Authors:  Holger Jahn
Journal:  Dialogues Clin Neurosci       Date:  2013-12       Impact factor: 5.986

10.  Cross-sectional and longitudinal characterization of SCD patients recruited from the community versus from a memory clinic: subjective cognitive decline, psychoaffective factors, cognitive performances, and atrophy progression over time.

Authors:  Elizabeth Kuhn; Inès Moulinet; Audrey Perrotin; Renaud La Joie; Brigitte Landeau; Clémence Tomadesso; Alexandre Bejanin; Siya Sherif; Vincent De La Sayette; Béatrice Desgranges; Denis Vivien; Géraldine Poisnel; Gaëlle Chételat
Journal:  Alzheimers Res Ther       Date:  2019-07-08       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.